Detection and clinical significance of circulating tumour cells in patients with colorectal carcinoma
Authors:
P. Ihnát 1,2; J. Srovnal 3; J. Hrubovčák 1,2; L. Martínek 1,2
Authors‘ workplace:
Chirurgická klinika, Fakultní nemocnice Ostrava, Česká republika
1; Katedra chirurgických oborů, Lékařská fakulta Univerzity Palackého, Olomouc, Česká republika
2; Ústav molekulární a translační medicíny, Lékařská fakulta Univerzity Palackého, Olomouc, Česká republika
3
Published in:
Rozhl. Chir., 2023, roč. 102, č. 10, s. 376-380.
Category:
Review
doi:
https://doi.org/10.33699/PIS.2023.102.10.376–380
Overview
Circulating tumour cells (CTCs) are tumour cells identified in the peripheral blood of patients with malignant disease. CTCs present a very interesting biomarker with promising potential for use in the treatment management of patients with colorectal cancer. Unlike other tumour biomarkers, CTCs are living tumour cells that carry molecular and biological information about the tumour as a whole and reflect ongoing mutational changes. Detection of CTCs from peripheral blood presents a simple and easily repeatable method of liquid biopsy. However, various techniques of CTC selection and detection render clinical use of CTC as a clinical biomarker difficult. The presence/amount of CTCs correlates very well with prognosis and patients ́ survival. Since CTCs have metastatic potential, knowledge of the effect of different treatment modalities on the amount of CTCs in the blood appears to be very important. It can be expected that a more effective treatment regimen will be associated with a reduction in blood CTC levels, and also with a better prognosis. Conversely, an increase or persistence of CTC levels will be associated with resistance to the applied treatment. Routine use of CTCs in clinical practice is limited predominantly by price and very high variability of available scientific evidence. Recently published studies demonstrated the promising potential of CTCs; however, further research will be required for their routine use in clinical practice.
Keywords:
colorectal cancer – Prognosis – biomarker – circulating tumour cells – treatment monitoring
Sources
1. Glynne-Jones R, Wyrwicz L, Tiret E, et al. ESMO Guidelines Committee. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4): iv263.
2. Ihnát P, Vávra P, Zonča P. Treatment strategies for colorectal carcinoma with synchronous liver metastases: Which way to go? World J Gastroenterol. 2015 Jun 14;21(22):7014−7021. doi: 10.3748/wjg. v21.i22.7014.
3. Machado Carvalho JV, Dutoit V, Corrò C, et al. Promises and challenges of predictive blood biomarkers for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Cells 2023; 12(3):413. doi: 10.3390/cells12030413.
4. Galoș D, Gorzo A, Balacescu O, et al. Clinical applications of liquid biopsy in colorectal cancer screening: Current challenges and future perspectives. Cells 2022;11(21):3493. doi: 10.3390/ cells11213493.
5. Petrik J, Verbanac D, Fabijanec M, et al. Circulating tumor cells in colorectal cancer: Detection systems and clinical utility. Int J Mol Sci. 2022;23(21):13582. doi: 10.3390/ijms232113582.
6. Ashworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 1869;14:146–147.
7. Lin D, Shen L, Luo M, et al. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther. 2021;6(1):404. doi: 10.1038/s41392-02100817-8.
8. Jiang M, Jin S, Han J, et al. Detection and clinical significance of circulating tumor cells in colorectal cancer. Biomark Res. 2021;9(1):85. doi: 10.1186/s40364-02100326-4.
9. Masuda T, Hayashi N, Iguchi T, et al. Clinical and biological significance of circulating tumor cells in cancer. Mol Oncol. 2016;10(3):408−417. doi: 10.1016/j.molonc.2016.01.010.
10. Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 2003;3(6):453– 458.
11. Yadav A, Kumar A, Siddiqui MH. Detection of circulating tumour cells in colorectal cancer: Emerging techniques and clinical implications. World J Clin Oncol. 2021;12(12):1169−1181. doi: 10.5306/ wjco.v12.i12.1169.
12. Moon DH, Lindsay DP, Hong S, et al. Clinical indications for, and the future of, circulating tumor cells. Advanced Drug Delivery Reviews 2018;125:143−150. doi: 10.1016/j.addr.2018.04.002.
13. Huang X, Gao P, Song Y, et al. Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch system in colorectal cancer. BMC Cancer 2015;15:202. doi: 10.1186/s12885-0151218-9.
14. Tsutsuyama M, Nakanishi H, Yoshimura M, et al. Detection of circulating tumor cells in drainage venous blood from colorectal cancer patients using a new filtration and cytology-based automated platform. PLoS One 2019;14(2):e0212221. doi: 10.1371/journal.pone.0212221.
15. Kolostova K, Rzechonek A, Schützner J, et al. Tumor cells as an auxiliary diagnostic tool in surgery. In Vivo 2017;31(6):1197−1202. doi: 10.21873/ invivo.11190.
16. Vasantharajan SS, Barnett E, Gray ES, et al. Assessment of a size-based method for enriching circulating tumour cells in colorectal cancer. Cancers (Basel) 2022;14(14):3446. doi: 10.3390/cancers 14143446.
17. Jiang J, Zhao H, Shu W, et al. An integrated microfluidic device for rapid and high-sensitivity analysis of circulating tumor cells. Sci Rep. 2017;7:42612. doi: 10.1038/srep42612.
18. Saucedo-Zeni N, Mewes S, Niestroj R, et al. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol. 2012;41(4):1241−1250. doi: 10.3892/ijo.2012.1557.
19. Tsai WS, You JF, Hung HY, et al. Novel circulating tumor cell assay for detection of colorectal adenomas and cancer. Clin Trans Gastroenterol 2019 Oct;10(10):e00088. doi: 10.14309/ctg.0000000000000088.
20. Rahbari NN, Aigner M, Thorlund K, et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology 2010; 138(5):1714−1726. doi: 10.1053/j.gastro. 2010.01.008.
21. Katsuno H, Zacharakis E, Aziz O, et al. Does the presence of circulating tumor cells in the venous drainage of curative colorectal cancer resections determine prognosis? A meta-analysis. Ann Surg Oncol. 2008;15(11):3083−3091. doi: 10.1245/s10434-008-0131-8.
22. Groot Koerkamp B, Rahbari NN, Büchler MW, et al. Circulating tumor cells and prognosis of patients withresectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann Surg Oncol. 2013;20(7):2156−2165. doi: 10. 1245/s10434-013-2907-8.
23. Pan RJ, Hong HJ, Sun J, et al. Detection and clinical value of circulating tumor cells as an assisted prognostic marker in colorectal cancer patients. Cancer Manag Res. 2021;13:4567−4578. doi: 10.2147/ CMAR.S300554.
24. Yang C, Shi D, Wang S, et al. Prognostic value of preand post-operative circulating tumor cells detection in colorectal cancer patients treated with curative resection: a prospective cohort study based on ISET device. Cancer Manag Res. 2018;10:4135−4144. doi: 10.2147/CMAR. S176575.
25. Papavasiliou P, Fisher T, Kuhn J, et al. Circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer. Proc. (Bayl Univ Med Cent) 2010;23(1):11−14. doi: 10.1080/08998280.2010.
26. Kawahara H, Watanabe K, Toyama Y, et al. Determination of circulating tumor cells for prediction of recurrent colorectal cancer progression. Hepatogastroenterology 2012;59(119):2115–2118. doi: 10.5754/ hge11970.
27. Tol J, Koopman M, Miller MC, et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol. 2010;21(5):1006−1012. doi: 10.1093/annonc/mdp463.
28. Guadagni S, Clementi M, Mackay AR, et al. Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study. J Cancer Res Clin Oncol. 2020; 146(5):1273−1290. doi: 10.1007/s00432020-03156-3.
29. Pascual J, Attard G, Bidard FC, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022; 33(8):750−768. doi: 10.1016/j.annonc.2022.05.520.
Labels
Surgery Orthopaedics Trauma surgeryArticle was published in
Perspectives in Surgery
2023 Issue 10
Most read in this issue
- Postoperative delirium
- Novel surgical procedure in design of advancement endorectal flap in the surgical treatment of complex anal fistulas
- Ileus conditions after rectal and Hartmann’s resections
- Detection and clinical significance of circulating tumour cells in patients with colorectal carcinoma